Anti-malarial landscape in Myanmar: results from a nationally representative survey among community health workers and the private sector outlets in 2015/2016

Table 3 CHW availability of anti-malarial drugs and malaria diagnostics, among anti-malarial-stocking outlets, by region

	CHW Total(N = 1263) (95% CI)	Eastern (N = 545) (95% CI)	Central (N = 244) (95% CI)	Western (N = 242) (95% CI)	Coastal N = (232) (95% CI)
Availability of anti-malarials^a
Any ACT^b	83.1 (80.1, 86.1)	87.8 (83.9, 90.9)	76.2 (69.8, 81.6)	83.3 (76.1, 88.6)	91.7 (86.2, 95.1)
Chloroquine	67.0 (63.5, 70.5)	67.6 (63.0, 71.8)	65.4 (58.8, 71.4)	76.0 (68.4, 82.3)	67.3 (59.0, 74.6)
Primaquine	62.6 (58.6, 66.5)	60.3 (55.3, 65.2)	58.1 (50.4, 65.3)	72.7 (64.2, 79.8)	74.7 (67.5, 80.8)
Oral AMT	2.9 (1.6, 4.2)	2.4 (1.2, 4.7)	4.0 (2.1, 7.5)	4.5 (2.6, 7.9)	0.6 (0.2, 2.2)
Non-oral AMT	8.9 (6.5, 11.3)	6.5 (4.1, 10.2)	12.3 (8.3, 17.8)	7.9 (5.1, 12.0)	5.0 (2.4, 10.2)

	N = 1382	N = 597	N = 277	N = 257	N = 251
Availability of blood testing^c
Any malaria blood testing	77.7 (74.4, 81.0)	79.3 (75.5, 82.7)	72.5 (65.6, 78.4)	83.6 (78.1, 87.9)	86.1 (79.7, 90.7)
Malaria microscopy	0.2 (0.0, 0.5)	0.1 (0.0, 0.7)	0.3 (0.0, 2.1)	1.1 (0.2, 5.9)	0.0
RDTs	77.7 (74.4, 81.0)	79.3 (75.5, 82.7)	72.5 (65.6, 78.4)	83.6 (78.1, 87.9)	86.1 (79.7, 90.7)

AMT artemisinin monotherapy
^aAnti-malarial-stocking outlets have at least one anti-malarial in stock on the day of the survey, verified by presence of at least one anti-malarial recorded in the ant-imalarial audit sheet
^bAt the time of the 2015/2016 Myanmar ACTwatch outlet survey, AL, DHA-PP, and ASMQ were the first-line treatments for uncomplicated falciparum malaria. There was no ASMQ audited during the 2015/2016 survey
^cBlood testing availability is reported among outlets that either had anti-malarials in stock on the day of the survey or reportedly stocked anti-malarials in the previous 3 months

ISSN: 1475-2875